Childhood malignant neoplasm

Summary

Childhood malignant neoplasm (MONDO:0006517) is a cancer (an umbrella term covering 30 Mondo subtypes) and 719 clinical trials. Top therapeutic interventions include ondansetron, palonosetron, and chlorpromazine. A subtype of cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 30 Mondo subtypes
• Clinical trials: 719

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	childhood malignant neoplasm
Mondo ID	MONDO:0006517
EFO	EFO:1000654
NCIT	C4005
UMLS	C0278704
MedGen	82962
Is cancer (heuristic)	yes

Also known as: childhood cancer · childhood malignant neoplasm · childhood neoplasm, malignant · malignant childhood neoplasm · malignant childhood tumor · malignant childhood tumour · malignant neoplasm · malignant paediatric neoplasm · malignant paediatric tumour · malignant pediatric neoplasm · malignant pediatric tumor · paediatric cancer · pediatric cancer

Disease family

This is a subtype of cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › childhood malignant neoplasm

Related subtypes (32): respiratory system cancer, immune system cancer, musculoskeletal system cancer, integumentary system cancer, peritoneum cancer, cardiovascular cancer, reproductive system cancer, malignant giant cell tumor, digestive system cancer, lipomatous cancer, thoracic cancer, malignant glomus tumor, malignant mesenchymoma, carcinoma, sarcoma, blastoma, head and neck cancer, malignant mixed neoplasm, nervous system cancer, retroperitoneal cancer, malignant germ cell tumor, malignant mesothelioma, malignant urinary system neoplasm, anaplastic cancer, malignant spindle cell neoplasm, high grade malignant neoplasm, malignant endocrine neoplasm, malignant soft tissue neoplasm, secondary malignant neoplasm, refractory malignant neoplasm, malignant adenoma, cancer of unknown primary site

Subtypes (30): childhood oligodendroglioma, pediatric osteosarcoma, pediatric fibrosarcoma, childhood choroid plexus carcinoma, childhood central nervous system primitive neuroectodermal neoplasm, childhood brain stem neoplasm, pediatric angiosarcoma, pediatric mesenchymal chondrosarcoma, pediatric liposarcoma, pediatric lymphoma, childhood malignant mesenchymoma, pediatric myxoid chondrosarcoma, childhood botryoid rhabdomyosarcoma, pediatric intraocular retinoblastoma, childhood cerebral astrocytoma, childhood epithelioid sarcoma, childhood pleomorphic rhabdomyosarcoma, pediatric infratentorial ependymoma, pediatric supratentorial ependymoma, childhood malignant schwannoma, pediatric extraocular retinoblastoma, childhood leukemia, childhood precursor T-lymphoblastic lymphoma/leukemia, malignant childhood germ cell neoplasm, pleuropulmonary blastoma, pediatric hepatocellular carcinoma, childhood malignant kidney neoplasm, childhood malignant melanoma, extrarenal rhabdoid tumor, pediatric high-grade glioma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

2 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Dasatinib Anhydrous	Approved (phase 4)
Plerixafor	Approved (phase 4)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Cannabinol, Perindopril, Quercetin.

Clinical trials & evidence

Clinical trials

Clinical trials: 719.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	500
PHASE1	69
PHASE2	56
PHASE1/PHASE2	28
PHASE3	25
PHASE2/PHASE3	15
EARLY_PHASE1	14
PHASE4	12

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06145321	PHASE4	ACTIVE_NOT_RECRUITING	Continuous Versus Bolus Administration of G-CSF in Children With Cancer
NCT07217600	PHASE4	RECRUITING	Ondansetron Orodispersible Film for Vomiting Prevention in Pediatric Radiotherapy
NCT07590648	PHASE4	NOT_YET_RECRUITING	Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia
NCT01143974	PHASE4	COMPLETED	Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer
NCT01896440	PHASE4	WITHDRAWN	Heart Safety Study of Ondansetron in Children Receiving Chemotherapy
NCT02967341	PHASE4	UNKNOWN	Blood Draw Validation for Ciprofloxacin Pharmacokinetic Research in Pediatric Cancer Patients
NCT03176849	PHASE4	COMPLETED	A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT
NCT03397914	PHASE4	COMPLETED	Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections
NCT03823950	PHASE4	UNKNOWN	Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients
NCT04187755	PHASE4	COMPLETED	Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever
NCT05844670	PHASE4	UNKNOWN	CHildren Treated With Vincristine: A Trial Regarding Pharmacokinetics, DNA And Toxicity of Targeted Therapy In Pediatric Oncology Patients.
NCT06023368	PHASE4	WITHDRAWN	Reducing Port Access Pain and Clinic Wait Time: An Evaluation of EMLA Cream Versus nüm™ Vapocoolant Spray
NCT02491632	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer
NCT03021486	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer
NCT03525873	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy
NCT03741673	PHASE3	RECRUITING	Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
NCT03743649	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care
NCT04749108	PHASE2/PHASE3	RECRUITING	Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma
NCT05770037	PHASE2/PHASE3	RECRUITING	DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
NCT05770102	PHASE2/PHASE3	RECRUITING	DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
NCT05770544	PHASE2/PHASE3	RECRUITING	DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
NCT06836492	PHASE3	RECRUITING	A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.
NCT06988475	PHASE2/PHASE3	RECRUITING	DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
NCT07035821	PHASE3	NOT_YET_RECRUITING	Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy
NCT07440290	PHASE2/PHASE3	NOT_YET_RECRUITING	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
NCT00305851	PHASE3	COMPLETED	Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant
NCT00575926	PHASE3	COMPLETED	Lingzhi for Cancer Children
NCT01343680	PHASE3	TERMINATED	Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients
NCT01365156	PHASE3	COMPLETED	Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
NCT01434394	PHASE2/PHASE3	COMPLETED	Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer
NCT01661335	PHASE3	COMPLETED	Efficacy of Aprepitant (Emend®) in Children
NCT01817075	PHASE3	COMPLETED	Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant
NCT01836432	PHASE3	TERMINATED	Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
NCT01858571	PHASE3	COMPLETED	Low Dose Chemotherapy Versus Best Supportive Care in Progressive Pediatric Malignancies
NCT02236936	PHASE3	TERMINATED	Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck
NCT02404051	PHASE3	UNKNOWN	Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer
NCT02585713	PHASE3	COMPLETED	Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
NCT03003273	PHASE3	TERMINATED	Early Stoppage Versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients With Febrile Neutropenia, Before Recovery of Counts: -DALFEN Study
NCT03040726	PHASE2/PHASE3	COMPLETED	Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
NCT03578081	PHASE3	COMPLETED	Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ONDANSETRON	4	9
PALONOSETRON	4	5
CHLORPROMAZINE	4	3
2-MERCAPTOETHANESULFONIC ACID	4	2
CAPMATINIB	4	2
CEMIPLIMAB	4	2
HALOPERIDOL	4	2
LIDOCAINE HYDROCHLORIDE	4	2
NETUPITANT	4	2
OLAPARIB	4	2
ALECTINIB	4	1
APIXABAN	4	1
APREPITANT	4	1
ARSENIC TRIOXIDE	4	1
ASPARAGINASE	4	1
ATORVASTATIN CALCIUM	4	1
AVELUMAB	4	1
BRIGATINIB	4	1
BUPIVACAINE HYDROCHLORIDE	4	1
CAPIVASERTIB	4	1
CEFEPIME	4	1
CEFTAZIDIME	4	1
CETUXIMAB	4	1
CHLOROTRIANISENE	4	1
CIPROFLOXACIN	4	1
CLAVULANIC ACID	4	1
COBIMETINIB	4	1
COLISTIMETHATE SODIUM	4	1
CRIZOTINIB	4	1
CYPROHEPTADINE	4	1